Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...
Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...
Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says.
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...
Data suggests that bowel cancers are on the rise among people younger than 50. Studies have found that younger people are ...
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...
GlobalData on MSN12d
FDA approves Amgen’s combo therapy for colorectal cancerAmgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.
New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback